DEXCOM ($DXCM) posted quarterly earnings results on Thursday, May 1st. The company reported earnings of $0.32 per share, missing estimates of $0.33 by $0.01. The company also reported revenue of $1,036,000,000, missing estimates of $1,037,730,405 by $-1,730,405.
You can see Quiver Quantitative's $DXCM stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
DEXCOM Insider Trading Activity
DEXCOM insiders have traded $DXCM stock on the open market 20 times in the past 6 months. Of those trades, 0 have been purchases and 20 have been sales.
Here’s a breakdown of recent trading of $DXCM stock by insiders over the last 6 months:
- KEVIN R SAYER (Chairman, CEO & President) has made 0 purchases and 2 sales selling 65,857 shares for an estimated $5,186,579.
- JEREME M SYLVAIN (EVP, Chief Financal Officer) has made 0 purchases and 7 sales selling 25,335 shares for an estimated $1,864,588.
- SADIE STERN (EVP, Chief HR Officer) has made 0 purchases and 4 sales selling 17,952 shares for an estimated $1,319,347.
- JACOB STEVEN LEACH (EVP, Chief Operating Officer) has made 0 purchases and 3 sales selling 17,454 shares for an estimated $1,276,793.
- MICHAEL JON BROWN (EVP, Chief Legal Officer) sold 13,000 shares for an estimated $914,941
- MATTHEW VINCENT DOLAN (EVP, Strategy & Corporate Dev) sold 1,183 shares for an estimated $102,819
- BRIDGETTE P HELLER has made 0 purchases and 2 sales selling 1,352 shares for an estimated $101,626.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
DEXCOM Hedge Fund Activity
We have seen 459 institutional investors add shares of DEXCOM stock to their portfolio, and 460 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- WELLINGTON MANAGEMENT GROUP LLP removed 5,672,673 shares (-99.5%) from their portfolio in Q4 2024, for an estimated $441,163,779
- BLACKROCK, INC. added 4,574,990 shares (+13.1%) to their portfolio in Q4 2024, for an estimated $355,796,972
- CAPITAL WORLD INVESTORS removed 3,785,016 shares (-49.6%) from their portfolio in Q4 2024, for an estimated $294,360,694
- CAPITAL RESEARCH GLOBAL INVESTORS removed 3,576,503 shares (-19.9%) from their portfolio in Q4 2024, for an estimated $278,144,638
- CITADEL ADVISORS LLC added 3,027,597 shares (+245.4%) to their portfolio in Q4 2024, for an estimated $235,456,218
- MILLENNIUM MANAGEMENT LLC added 2,734,321 shares (+800.3%) to their portfolio in Q4 2024, for an estimated $212,648,144
- MORGAN STANLEY added 1,652,586 shares (+31.4%) to their portfolio in Q4 2024, for an estimated $128,521,613
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
DEXCOM Congressional Stock Trading
Members of Congress have traded $DXCM stock 3 times in the past 6 months. Of those trades, 1 have been purchases and 2 have been sales.
Here’s a breakdown of recent trading of $DXCM stock by members of Congress over the last 6 months:
- REPRESENTATIVE ROBERT BRESNAHAN has traded it 2 times. They made 1 purchase worth up to $15,000 on 02/25 and 1 sale worth up to $15,000 on 04/08.
- REPRESENTATIVE KEVIN HERN sold up to $100,000 on 12/31.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.
DEXCOM Analyst Ratings
Wall Street analysts have issued reports on $DXCM in the last several months. We have seen 3 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Wells Fargo issued a "Overweight" rating on 03/08/2025
- Bernstein issued a "Outperform" rating on 01/08/2025
- Citigroup issued a "Buy" rating on 12/11/2024
To track analyst ratings and price targets for DEXCOM, check out Quiver Quantitative's $DXCM forecast page.
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
